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Abstract.  This study characterizes effects of nerve 
growth factor (NGF)  on the steady-state level and 
phosphorylation of a  high molecular mass microtubule- 
associated protein in PC12  rat pheochromocytoma 
cells. Past work showed that NGF significantly raises 
the relative levels of this phosphoprotein, designated 
MAP1.2, with a  time course similar to that of neurite 
outgrowth. To study this in greater detail, MAP1.2  in 
PC12  cell lysates was resolved by SDS-PAGE in gels 
containing 3.25%  acrylamide/4 M  urea and identified 
by comigration with material immunoprecipitated from 
the lysates by MAP1  antibodies. Quantification by 
metabolic radiolabeling with pS]methionine or by sil- 
ver staining revealed a  3.0-3.5-fold increase in 
MAP1.2 levels relative to total cell protein after NGF 
treatment for 2  wk or longer.  A  partial increase was 
detectable after 3 d, but not after 2  h  of NGF ex- 
posure.  As measured by incorporation of [32p]phos- 
phate, NGF had a dual effect on MAP1.2.  Within  15 
min to 2 h,  NGF enhanced the incorporation of phos- 
phate into MAP1.2 by two- to threefold relative to total 
cell phosphoproteins. This value slowly increased 
thereafter so that by 2  wk or more of NGF exposure, 
the average enhancement of phosphate incorporation 
per MAP1.2  molecule was over fourfold. The rapid 
action of NGF on MAP1.2 could not be mimicked by 
either epidermal growth factor, a  permeant cAMP 
derivative, phorbol ester, or elevated K +, each of 
which alters phosphorylation of other PC12  cell pro- 
teins.  SDS-PAGE revealed multiple forms of MAP1.2 
which, based on the effects of alkaline phosphatase on 
their electrophoretic mobilities, differ, at least in part, 
in extent of phosphorylation. Before NGF treatment, 
most PC12  cell MAP1.2 is in more rapidly migrating, 
relatively poorly phosphorylated forms. After long- 
term NGF exposure, most is in more slowly migrat- 
ing, more highly phosphorylated forms. The effects of 
NGF on the rapid phosphorylation of MAP1.2 and on 
the long-term large increase in highly phosphorylated 
MAP1.2  forms could play major functional roles in 
NGF-mediated neuronal differentiation. Such roles 
may include effects on microtubule assembly, stability, 
and cross-linking and, possibly for the rapid effects, 
nuclear signaling. 
T 
HE most prominent characteristic of neuronal differ- 
entiation is  the elaboration of extensive axonal and 
dendritic arbors. These structures are densely packed 
with microtubules which are required for the growth of neu- 
rites (9,  36).  The biological rules governing the initiation 
and extension of these structures are not fully understood but 
are likely to involve accessory molecules known as microtu- 
bule-associated proteins (MAPs) ~ (for review see reference 
28).  Among  these  is  the  high  molecular  mass  species, 
MAP1, the levels of which are developmentally up regulated 
in mammalian brain (2,  29).  Although the distribution of 
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MAP1  in the nervous system is widespread (5), recent im- 
munological evidence (4) suggests that a MAP1 subspecies, 
MAP1B, may be more abundant than MAP1A in axons. At 
least in vitro, MAP1 promotes the assembly of microtubules 
(18) and forms filamentous arms on their surfaces (34).  In 
addition, stabilization of microtubules and cross-linking of 
microtubules  to  one another or to  other  elements of the 
cytoskeleton are also among the possible functional roles of 
MAP1. 
The role of MAPs in process outgrowth by intact neuronal 
cells has recently been studied using a model system, the 
PC12 clonal line of rat pheochromocytoma cells. In the pres- 
ence of nerve growth factor (NGF), these cells acquire a neu- 
ronal phenotype (13) and they may therefore be used to corre- 
late changes in composition with the onset and elongation of 
neurites. In particular, NGF has been found to greatly in- 
crease the relative levels of a phosphoprotein that is recog- 
nized by antisera prepared against high molecular mass brain 
©  The Rockefeller University Press, 0021-9525/88/05/1573/9 $2.00 
The Journal of Cen Biology,  Volume  106, May  1988  1573-1581  1573 MAPs, associates with microtubules, comigrates with a sub- 
species of rat brain MAP1  by SDS-PAGE analysis, and like 
MAP1, but unlike MAP2, precipitates upon boiling (15). It 
was unclear whether the influence of NGF on this species, 
designated MAP1.2 (15), is due either to an increase in the 
levels of this protein, to an enhancement of its phosphoryla- 
tion,  or to a  combination of both of these effects. Subse- 
quently, Drubin et al. (10) used a mAb in an attempt to quan- 
tify PC12 cell MAP1  and came to the conclusion that NGF 
induces an increase in the levels of this protein by ~20-fold. 
On the other hand, Lewis et al. (22) examined MAP1 mRNA 
levels in PC12 cells by means of a specific cDNA probe, and 
noted that NGF brought about at most only a severalfold rel- 
ative increase in this message. 
In  view  of the  large  NGF-induced  increase  in  phos- 
phorylated MAP1.2 levels and of the relatively modest effect 
of the factor on MAP1 mRNA, we have directly reexamined 
the actions of NGF on the steady-state levels and the extent 
of phosphorylation of this protein. This type of information 
will  be  important  in  understanding  the  relative  roles  of 
MAP1  synthesis and posttranslational modification in NGF- 
promoted acquisition and maintenance of neuronal morphol- 
ogy.  Our  results  indicate  that  NGF  brings  about  a  rapid 
(minutes),  specific increase  in the  incorporation of phos- 
phate into PC12 cell MAP1.2, as well as a more slowly de- 
veloping (days) increase in both the extent of phosphorYla- 
tion and the relative levels of this protein. We also detect 
multiple forms of MAP1.2 that differ, at least in part, in de- 
gree of phosphorylation. The net long-term action of NGF, 
by virtue of its effects on MAP1.2 levels and phosphoryla- 
tion, is to greatly enhance the cellular content of  highly phos- 
phorylated forms of MAP1.2. 
Materials and Methods 
Reagents 
NGF  was  prepared  from  mouse  salivary  glands  (Bio-Trol,  Inc.,  Indi- 
anapolis, IN) by the procedure of Mobley et al. (26). Epidermal growth fac- 
tor (EGF) was a gift from Dr. Fred Maxfield, Department of Pharmacology, 
NYU Medical Center, New York. Alkaline phosphatases from Escherichia 
coli or from bovine intestinal mucosa were purchased from Sigma Chemical 
Co.,  St.  Louis,  MO.  8(4-Chlorophenylthio)-cyclic-adenosine-3':5'  mono- 
phosphate was from Boehringer Mannheim Biochemicals, Indianapolis, IN 
and 12-0-tetradecanoyl-phorbol-13-acetate  from Calbiochem-Behring Corp., 
La  Jolla,  CA.  Pyrophosphate tetrasodium and  the protease inhibitors- 
pepstatin A, leupeptin, benzamidine, phenylmethylsulfonyl  fluoride (PMSF), 
and trasylol-were all  from Sigma Chemical Co.  Reagents used for dec- 
trophoresis were obtained from either Sigma Chemical Co.  or Bio-Rad 
Laboratories, Richmond, CA and Tris buffers from Sigma Chemical Co. 
Protein determinations by the method of Bradford (6) were carried out 
with reagents supplied by Bio-Rad Laboratories, using BSA (fraction V; 
Sigma Chemical Co.) as the standard. 
Antibody Preparations 
A rabbit polyclonal antiserum, 3d2, was raised against a gel-purified fusion 
protein consisting of a portion of the E. coli trpE protein fused to a protein 
encoded by a partial mouse MAPl cDNA clone (clone D, Figs. 2 and 3 in 
reference 22). This antiserum was shown to be specific for MAPI.2 on West- 
ern blots of purified mouse brain microtubules (Lewis, S. A., and N. J. Co- 
wan, unpublished observation). Clone D detects an mRNA species of ,~10 
kb in PC12 cells and in rat brain (22).  In addition, three previously de- 
scribed anti-MAP antibodies were used: a rabbit anti-bovine MAPI poly- 
clonal antiserum (23); a rabbit anti-bovine MAP polyclonal antiserum (32) 
provided by Dr. P. Sherline, Division of Endocrinology, Cornell Medical 
College, New York,  NY;  and a  mouse monoclonal MAP1  antibody (10) 
provided by Dr.  D. Asai, Dept. of Biological Sciences, Purdue University, 
Lafayette,  IN. 
Cell Culture and Radiolabeling of  Proteins 
PCI2 cells were cultured with or without NGF as previously described (13). 
NGF-treated cells were maintained in 1% donor horse serum to maximize 
the density of neurite outgrowth with a minimum of cell clumping (see refer- 
ences 1 and 3).  Several  experiments performed on a substrate (matrigel; 
Collaborative Research, Inc., Waltham, MA) that minimizes cell clumping 
even further gave results simlar to those carried out on air-dried collagen. 
Experiments requiring comparisons among cultures subjected to differ- 
ent experimental treatments were executed using  sister cultures of cells 
plated and harvested in parallel.  Metabolic radiolabeling of proteins was 
carried out using either 50 I.tCi of [35S]methionine (1,000-1,200  Ci/mmol) 
in 1 ml of complete culture medium for 3 d, or 20-100 ~Ci/ml of [32PJor- 
thophosphate in a modified Krebs-Ringer solution (15) for 1.5-2 h. Both iso- 
topes were purchased from New England Nuclear, Boston, MA. For NGF- 
treated cultures, NGF was also continuously present during exposure to the 
isotopes. 
Immunoprecipitation and Immunoblotting of  MAP1.2 
For immunoprecipitations, cells were solubilized in a detergent-containing 
buffer (1) and then incubated with one of two different MAPI antisera-3d2 
(see above) or an anti-MAP1  polyclonal serum  (23).  Antigen-antibody 
complexes were then precipitated with protein A-Sepharose beads (Pharma- 
cia Fine Chemicals, Piscataway, N J), solubilized in SDS sample buffer (15), 
and subjected to electrophoresis on a one-dimensional slab gel as described 
below.  Immunoprecipitated MAPI.2 was then located on the gel either by 
silver staining, or, when cellular proteins had been metabolically radiola- 
beled, by autoradiography.  Immunoblotting was carried out by the method 
of Wiche et al.  (35). 
Phosphatase Experiments 
Cells were rinsed while still  attached to culture dishes three times with 
warm (37~C) PBS (11) and then harvested at 4°C in 100 mM Tris-HCI buffer 
(pH 8.2) containing 1-3 mM MgC12, 2 mM PMSF, 100 klU/ml trasylol, 10 
I.tg/ml leupeptin, 10 p.g/ml pepstatin A, and 10 I.tM benzamidine. The sus- 
pension was homogenized with 20 strokes in a hand-held teflon glass mortar 
and pestle and allowed to stand on ice for 10 rain. The supernatnat (produced 
by centrifugation in an Eppendorf microfuge for 10 min) was then aliquoted 
into tubes containing either diluent only, 10 U/ml E. coil alkaline phospha- 
tase, or 5 or 10 I.tg/ml calf intestine alkaline phosphatase. Some tubes also 
contained 15-20 mM pyrophosphate tetrasodium. Incubation times were 
varied from 1-18 h at 35°C or 6-18 h at room temperature. The protocol which 
proved optimal for detection of the shift in MAPI.2 mobility by SDS-PAGE 
used the calf enzyme, 10 mg)inl, at room temperature for 18 h. 
At the end of the incubation period, a fourfold concentrate of SDS sample 
buffer was added (1:3) to each reaction tube, mixed, and heated in a boiling 
water bath for 5 min. After separation by SDS-PAGE, proteins in the fixed 
gel were silver stained. 
Gel Electrophoresis 
Discontinuous SDS-PAGE (19) was performed using separating gels (16 cm) 
of the tbllowing composition: 4 M urea, 3.25% acrylamide, 375 mM Tris- 
HCI,  pH  8.8. Stacking gels composed of 3 %  acrylamide and  125  mM 
Tris-HCl  (pH  6.8)  were used.  Separating gels were fixed as previously 
described (1). 
Proteins were detected either by silver staining (Gelcode; Pierce Chemi- 
cal Co., Rockford, IL) or, when cultures had been metabolically radiola- 
beled, by autoradiography (XAR film;  Eastman Kodak, Co.,  Rochester, 
NY). 32P-labeled samples were equally loaded at  >/100,000 cpm/lane and 
35S-labeled samples at >/250,000 cpm/lane. Films were preflashed and ex- 
posure times were typically 12-36 h at room temperature. 
Some of the results obtained using the low percentage polyacrylamide- 
urea  gel  system were confirmed in experiments using  32-cm 6-12%  or 
5-15%  acrylamide gradient gels. 
Densitometric Quantification of  MAPI.2 Levels and 
Phosphorylation 
Individual lanes from autoradiograms or silver-stained gels were analyzed 
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ments, San Francisco, CA). The electrical output from each scan was ana- 
lyzed by a PC-operated software program (Macmillan Software Co., New 
York,  NY)  modified by  Steven  Drexler  (Department  of Pharmacology, 
NYU Medical Center) to perform plotting and integration of protein bands. 
The integrated values from autoradiograms of MAP1.2 fell within the linear 
range of the film's reciprocity as judged by a standard curve encompassing 
the 20-fold dilution of a 32p-labeled  source. A gel loaded with serial dilu- 
tions of a whole cell protein lysate was used to standardize the relationship 
between the density of the silver-stained MAP1.2 band and the amount of 
protein present. A linear association was found over a range of ,'~7.5-fold. 
Quantitative comparisons of control vs. NGF-treated cells were performed 
only with samples within this range. 
Results 
Identification and Detection of  MAPI.2 in PC12 Cells 
PC12 cells express a MAP1  subspecies designated MAP1.2 
05). Initial experiments to compare relative MAP1.2 protein 
levels  in  control  (nontreated)  and  long-term  NGF-treated 
PC12 cultures were performed by radioimmunoblotting anal- 
ysis (Fig.  l). Four different antibody preparations were used 
(see Materials and Methods),  two of which were monospe- 
cific for MAP1.2 and two of which were not.  Three of the 
antibody preparations  recognized MAP1.2  in both control 
and NGF-treated cultures and, when used on equal aliquots 
of the  same  PC12  lysates,  indicated  specific  increases  in 
MAP1.2  levels ranging  from 2.1-  to  3.3-fold  in  the  NGF- 
treated cultures (Fig.  1, A-C). However, the fourth prepara- 
tion (Fig.  1 D), a mAb, did not detect MAP1.2 in lysates of 
control cells, consequently indicating a much larger stimula- 
tion of levels by NGE 
Because of the variation in results with the antisera,  we 
chose to quantify the relative levels of MAP1.2 present under 
different experimental conditions  by direct electrophoretic 
comparison of whole cell  lysates.  To reliably  resolve this 
high molecular mass protein, we used electrophoresis in low 
percentage polyacrylamide gels containing urea. Identifica- 
tion was confirmed by comigration with material specifically 
immunoprecipitated from the cells by MAP1 antibodies (Fig. 
2).  To verify that the  band identified as MAP1.2  does not 
contain  significant amounts of other proteins,  cell extracts 
(labeled and unlabeled) were subjected to immunoprecipita- 
tion with excess 3d2 antiserum. This antiserum is monospe- 
cific for MAP1.2  (Fig.  1) and was prepared against fusion 
protein containing  a  sequence encoded by a  partial mouse 
cDNA clone for MAP1 (see Materials and Methods). PAGE 
analysis of the protein remaining after immunoprecipitation 
of the control lysates revealed, both by silver staining and by 
fluorography of 35S-labeled  material,  that  at  least  85%  of 
the MAP1.2 band was cleared.  In addition,  the 32p-labeled 
phosphoprotein  identified  as  MAP1.2  in  long-term  NGF- 
treated cells was found to be 90% cleared by the antiserum. 
Electrophoretic comparison of MAP1.2 in lysates of non- 
treated control cells with that in lysates of cells exposed to 
NGF for >2 wk reveals two major changes (Figs. 2-4). First, 
NGF brings about an increase in the intensity of MAPI.2 rel- 
ative to other cell proteins. Second, there is a consistent de- 
crease in the electrophoretic mobility of MAP1.2 from NGF- 
treated cells. These effects were observed in material labeled 
with either [35S]methionine  (for 3 d) or [35P]orthophosphate 
(for 1.5-3 h) and detected by autoradiography (Fig. 2) as well 
Figure 1. MAP1 in PCI2 cells detected by four different antibody 
preparations.  30 ~tg of protein from the same cell extracts of un- 
treated PC12 cells (-) or PCI2 cells treated with NGF for 3.5 wk 
(+),  was resolved on 3.3% polyacrylamide  gels containing 4  M 
urea, blotted to nitrocellulose, and the blots reacted with (A) a rab- 
bit polyclonal anti-bovine  brain high molecular weight MAP an- 
tiserum (32); (B) 3d2, a rabbit polyclonal antiserum raised against 
MAP1 fusion protein (see Materials  and Methods);  (C) a rabbit 
anti-MAP1  antiserum  (23);  and  (D) a  mouse  anti-MAP1  mAb 
(10). The bound antibodies were detected by ~25I-protein  A autora- 
diography.  Quantitative  densitometry  of the  autoradiograms  re- 
vealed NGF-induced increases in MAPI.2 of (A) 3.3-fold (B) 2.1- 
fold, and (C) 2.7-fold. No comparison could be made in D due to 
the low signal from control  cells.  Markers  show the position of 
MAPI.1, 1.2, and 2 from rat brain microtubules. Note that MAPI.1 
is detected by two of  the preparations (A and C) and that its mobility 
is also shifted after NGF treatment. 
as in material detected by silver staining (Fig. 3) or immuno- 
blotting (Fig.  1, A-C). 
Time Course and Quantification of the 
NGF-induced Effects on MAPI.2 
Past experiments (3,  10,  15) as well as those shown in Figs. 
2  and 4  reveal  a  long-term NGF-dependent increase in the 
relative levels of phosphate-labeled MAP1.2  in PC12  cells. 
This might result from either an increase in the steady-state 
level of the protein or an increased  incorporation of phos- 
phate or both. We therefore determined the contribution of 
each of these parameters by labeling  sister cultures  either 
with  [32p]orthophosphate  (for  1-3  h  to  measure  relative 
phosphate  incorporation)  or with  [35S]methionine  (for 3  d 
to  quantify  steady-state protein  levels).  Exposure to  NGF 
was varied from 0,  15 min, 2 h, 3 d, to 2 wk or more. Whole 
cell lysates were prepared from each culture, equal amounts 
of TCA-precipitable radioactivity subjected to SDS-PAGE, 
and  the  resolved  proteins  visualized  by  autoradiography 
(Fig.  4).  The  autoradiographs  were  then  scanned  den- 
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in whole cell lysates of long-term NGF- 
treated cells is detectable by silver stain- 
ing.  PC12 cells cultured  without  NGF 
(-) or with NGF for 2 wk (2 wk) were 
harvested in SDS sample buffer, imme- 
diately placed in a boiling water bath for 
5 min, and approximately equal quanti- 
ties  of protein  were  then  subjected  to 
SDS-PAGE. (-) 20  ~tg; (2 wk)  18  ltg 
protein. Arrows indicate the position of 
MAP1.2 as determined by silver staining 
of material specifically immunoprecipi- 
tated by anti-MAP 1 (data not shown; cf 
Fig.  1).  Both samples were run simul- 
taneously on the same gel. 
Figure 2.  Resolution and identification of MAP1.2 by SDS-PAGE 
and autoradiography by virtue of its comigration with immunopre- 
cipitated material. Sister cultures of PC12 cells maintained without 
NGF (-) or with NGF for 4 wk (+) were incubated with [35S]me- 
thionine  (3 d) or [32p]orthophosphate (2 h).  Lanes  1 and 2  and 
lanes  7 and 8 are from whole cell lysates of these cultures which 
were resolved by SDS-PAGE in a gel containing 3.25% acrylamide 
and 4 M urea. These lanes were loaded with 500,000 cpm/lane of 
TCA-precipitable 35S and  250,000 cpm/lane of TCA-precipitable 
3~p, respectively. The middle lanes (3-6) are from immunoprecip- 
itations carried out in parallel with material from the same cultures. 
A MAP1 antiserum  (3d2) generated against a fusion protein en- 
coded  by a  MAP1 cDNA clone  (22) was used  as described  in 
Materials and Methods to immunoprecipitate material from 32P-la- 
beled protein (lanes 5 and 6) or 35S-labeled protein (lanes 3 and 
4). A control experiment with samples incubated in the absence of 
the antiserum was clear of immunoprecipitable proteins (data not 
shown). Although in this experiment immunoprecipitation appears 
to show a disproportionately  large (12-fold) increase  in NGF-in- 
duced enhancement  of 35S-labeled MAP1.2, variable results have 
been obtained in six comparable independent immunoprecipitation 
experiments (ranging from 4-12-fold enhancement).  For this rea- 
son,  the immunoprecipitates are presented as indicating informa- 
tion about MAP1.2 electrophoretic  migration rather than relative 
MAP1.2 levels. Brackets indicate the area to which MAP1.2 mi- 
grates on the gel. The thin arrow marks the migration distance of 
MAP1.2 characteristic of the non-NGF-treated  cell while the thick 
arrow  denotes  the  position  of MAP1.2 from NGF-treated  cells. 
Migration distance of the 205-kD myosin protein standard is indi- 
cated. All lanes are derived  from the same gel. 
sitometrically to quantify the relative levels of radioactivity 
incorporated into MAP1.2. 
The values obtained from multiple experiments of the type 
described above are summarized in Table I. An increase in 
the relative steady-state level of MAP1.2 protein was detect- 
able after 3 d, but not after 2 h, of NGF exposure. In long- 
term NGF-treated (>2 wk) cultures, this measurement aver- 
aged 3.5-fold that in control cultures. The magnitude of this 
relative increase was similar to that determined by scanning 
densitometry of silver-stained gels,  or photographic nega- 
tives thereof, containing material from control and long-term 
NGF-treated  cells.  Four  independent  silver-stain  experi- 
ments gave the  following  results:  3.3  and  5.0  for directly 
scanned gels, and 1.9 and 2.4 for the photographic negatives. 
The mean value was 3.1  +  0.6 (SEM). The relative levels of 
MAP1.2 protein did not appear to increase further beyond 2 
wk of NGF treatment. 
The increase in phosphorylation of MAP1.2,  in contrast, 
commenced within 15 min of NGF exposure. Phosphoryla- 
tion of this species continued to increase further throughout 
the time course studied.  In agreement with previous studies 
(3,  15), the relative incorporation of phosphate into MAP1.2 
increased  by  an  average of  16-fold  after  >2  wk  of NGF 
treatment. 
Table I also shows the ratios of 32p/35S incorporation into 
MAP1.2 after various times of exposure to NGE This pro- 
vides an estimate of the relative average phosphate incorpo- 
ration per molecule.  After 2  h  of NGF treatment,  during 
which there was no detectable change in MAP1.2 protein lev- 
els, there was a threefold enhancement of relative phosphate 
incorporation  into  this  species.  In long-term NGF-treated 
cultures, normalization to the increase in MAPI.2 protein re- 
vealed an average enhancement of incorporation per mole- 
cule of over fourfold. These data thus show a rapid effect of 
NGF on MAP1.2 phosphorylation and that the large increase 
in phosphorylated MAP1.2 levels that occurs after long-term 
NGF treatment is due both to increased levels of MAP1.2 
protein and to an enhanced average incorporation of phos- 
phate per molecule. 
The observed effects of NGF on MAP1.2 phosphorylation 
could arise from either enhanced phosphate turnover or in- 
creased  steady-state  phosphorylation.  To  distinguish  be- 
tween  these  possibilities,  cultures  were  either  exposed to 
[32p]phosphate for 2 h  in the presence or absence of NGE 
prelabeled with [32p]phosphate for 3 d and then exposed to 
NGF or control medium for 2 h, or pretreated with NGF for 
2 wk and (in the continued presence of NGF) labeled with 
[32p]phosphate for either 2 h or 3 d. For both the short- and 
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phosphorylation and steady-state levels of MAP1.2.  Cellular pro- 
teins from sister cultures of untreated PC12 cells (-) and PC12 cells 
treated with NGF for 15 min, 2 h, 3 d, or 6 wk were metabolically 
radiolabeled  with [32P]orthophosphate (2 h) or [3SS]methionine (3 
d),  solubilized, and analyzed by SDS-PAGE (on a 3.25%  acryl- 
amide gel containing 4 M urea) and autoradiography.  Conditions 
for labeling  and NGF treatment were as follows. 15 min: NGF pres- 
ent during the last 15 rain of the labeling period; 2 h: NGF present 
during the entire incubation  with phosphate and during the last 2 h 
of incubation with methionine; 3d: phosphate  present during the 
last 2 h of NGF treatment, methionine present throughout;  6 wk: 
phosphate present during the final 2 h, methionine  during the final 
3 d. Thin arrows mark the migration distance of MAP1.2 from un- 
treated cells. Thick arrows mark the migration distance of MAP1.2 
from long-term NGF-treated cells. Each time point result is repre- 
sentative of three to five independent experiments.  Position of the 
205-kD standard is indicated. All lanes are derived from the same 
gel. 
long-term exposures to NGF, phosphorylation was similarly 
enhanced (as compared to controls) irrespective of whether 
labeling with phosphate was for 2 h or 3 d.  These findings 
indicate that the observed changes were in steady-state phos- 
phorylation and that this state is reached within 2  h. 
Figure 5. Alkaline phosphatase  treatment of MAP1.2.  Extracts  of 
PCI2 cells cultured without NGF (-) or with NGF for 8 wk (+) 
were  each  divided equally into four aliquots  as described under 
Materials  and Methods.  Alkaline phosphatase  (AP) from bovine 
intestinal  mucosa,  10  I.tg/ml, was  present  in  samples  5-8. 
Pyrophosphate  (PP),  16  mM,  an inhibitor of this  enzyme was 
added to samples 6 and 8. Aliquots I and 2 were solubilized in 2 % 
SDS sample buffer and heated in a boiling water bath immediately 
after preparation. Samples 3-8 were allowed to stand at room tem- 
perature  for  18 h before undergoing the  same solubilization and 
heating.  All of the aliquots were then subjected  to SDS-PAGE in 
a 3.25% acrylamide/4 M urea gel which was then fixed and silver 
stained.  Arrows mark the position of MAP1.2.  Asterisks identify 
an invariant band. Position of the 205-kD myosin protein standard 
is indicated.  Each aliquot from -  NGF cells contained 40 I.tg of 
protein at time zero and each  from  +  NGF cells,  50 I.tg. These 
results are representative  of three  independent experiments. 
Role of  Phosphorylation in the NGF-dependent 
Mobility Shift of  MAP1.2 
One  possible contribution to  the  NGF-promoted  shift  of 
MAP1.2 to a more slowly migrating position by SDS-PAGE 
analysis is elevated phosphorylation. If this is the case, then 
removal  of  phosphate  groups  should  increase  the  elec- 
trophoretic mobility of MAP1.2 in NGF-treated cell mate- 
rial. As illustrated in Figs. 5 and 6 A, incubation of extracts 
Table L  The Effect of  NGF on the Relative Radiolabeling  of  MAP1.2 
Relative densitometric levels of MAP1.2/duration of NGF treatment 
15 min  2  h  3  d  />2 wk 
32p-labeled MAPI.2  2.6  +  0.3*  3.0 +  0.4  5.9  +_  1.1  16.0 +  1.9 
(n =  3)  (n =  3)  (n =  4)  (n  =  16) 
35S-labeled MAP1.2  1.3  +  0.4  1.0  +  0.1  1.6  _  0.3  3.5  _  0.4 
(n =  3)  (n  =  3)  (n =4)  (n =5) 
32P/35S ratio  2.0  3.0  3.7  4.6 
The relative levels of 32p_ and 35S-labeled  MAP  1.2 in whole PC12 cells treated with NGF for 15 min, 2 h, 3 d, or >t2 wk were quantified densitometrically as 
described in Materials and Methods.  Levels are expressed here relative to those in non-NGF-treated  control cells plated and harvested in parallel with the ex- 
perimental cells (i.e., normalized to total incorporated TCA-precipitable cpm of 32p or 35S). Sister cultures were labeled with [3ZP]orthophosphate or [35S]methio- 
nine in three independent trials at the  15-min and 2-h points, four trials at 3  d of treatment, and five trials at the >/2 wk time point.  1 1 additional experiments 
with 32P-labeled  MAP  1.2 from long-term NGF-treated cells are included using 5-15%  or 6-12%  gradient gels. The average 32P/35S ratio for all 16 experiments 
is quite similar to that obtained from the five experiments matched with 35S-labeled  sister cultures (4.6 vs. 4.1,  respectively), n,  number of experiments. 
* SEM. 
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Figure 6.  Densitometric  scans  of MAP1.2  from  PC12 cells  in- 
cubated with alkaline phosphatase.  (A) Lanes 4-6 and (B) lanes 3, 
7, and 8 of Fig. 5 were scanned over 20 mm encompassing the area 
in  which  MAP1.2  migrates.  A  shows  the  scans  from long-term 
NGF-treated  cells. The solid line is the trace generated from an ali- 
quot without alkaline  phosphatase;  the dotted  line,  with  alkaline 
phosphatase;  and the dashed line with both the enzyme and  16 mM 
pyrophosphate,  an inhibitor of the phosphatase.  B depicts the scans 
from untreated cells. Here, the dashed line is the scan from the sam- 
ple without alkaline phosphatase;  the dotted line, with phosphatase; 
and the solid line, with the enzyme and the inhibitor,  16 mM. The 
MAP1.2 peak is marked by the bracket.  The arrow points to a pro- 
tein peak, marked by the asterisks  in Fig.  5, whose position was 
invariant  across  all treatments. 
from NGF-treated cells with alkaline phosphatase converted 
the MAP1.2 to a form with electrophoretic mobility charac- 
teristic  of that  in  nontreated  control  cells.  Similar  treat- 
ment of extracts from nontreated control cells also affected 
MAP1.2 so that it ran as a sharper band at the position of the 
front of the typically broad MAPI.2 band present in controls 
(Figs. 5 and 6 B).  Prelabeling of cells with [nP]orthophos- 
phate  confirmed  the  loss  of phosphate  during  enzymatic 
treatment.  Pyrophosphate, an inhibitor of alkaline phospha- 
tase (27), blocked these effects of enzymatic treatment.  This 
indicates that the enzyme-induced shift was due to changes 
in  phosphorylation  rather  than  to  proteolysis  by  a  con- 
taminant in the preparation. 
Activators of  Known Protein Kinases 
Do Not Mimic the NGF-mediated Rapid Increase 
in MAP1.2 Phosphorylation 
Agents known to promote phosphorylation reactions via ac- 
tivation of known protein kinases  were added to PC12 cul- 
tures  during  metabolic  radiolabeling  with  [nP]orthophos- 
phate  to  better  understand  the  mechanism  through  which 
Figure 7. Specificity of the rapid phosphorylation of MAP1.2. Sister 
cultures  were metabolically  labeled for 2.5 h with [32p]orthophos- 
phate either in the absence of any added agents (-), or in the pres- 
ence  of 44  mM  KCI  (K÷),  1 mM  8(4-chlorophenylthio)-cAMP 
(CPT), 200 nM tetradecanoyl-phorbol-13-acetate  (TPA), 50 ng/ml 
NGF,  or 5  ng/ml  EGF.  Equal  numbers of TCA-precipitabte  cpm 
(100,000) from each cell culture were subjected  to SDS-PAGE and 
autoradiography  as described in Materials  and  Methods.  The ar- 
rows mark the position  of MAPI.2 and the  solid  bar marks the 
205-kD standard. 
NGF acts to enhance the phosphorylation of MAPI.2.8-(4- 
Chlorophenylthio)-cyclic adenosine monophosphate,  a  per- 
meant  analog  of cAMP and  activator of protein  kinase  A 
(25);  12-O-tetradecanoyl-phorbol-13-acetate,  which  acti- 
vates protein  kinase C  (8);  or 44 mM KCI, which leads to 
activation of Ca++-dependent protein  kinases  via the open- 
ing of voltage-dependent Ca  ++ channels, were used. Each of 
these treatments  rapidly produces elevated phosphorylation 
of at least several PCI2 cell proteins (15, 16, 20, 24). This was 
confirmed during our studies in which these treatments lead 
to enhanced phosphorylation of at least one other cytoskele- 
tal  protein  in both NGF-treated and non-NGF-treated cul- 
tures (Aletta, J. M., and L. A. Greene, unpublished observa- 
tions).  It  is  noteworthy,  however,  that these  agents  do not 
promote neurite outgrowth in PC12 cell cultures.  EGF was 
also tested. This trophic polypeptide produces several effects 
on PCI2 cells similar to NGF, but not neurite outgrowth (17). 
EGF also triggers several rapid changes in PC12 cell protein 
phosphorylation (16). 
As shown in Fig. 7, none of the above treatments mimicked 
the rapid effect of NGF on MAP1.2 phosphorylation. In ad- 
dition,  the phosphorylation of MAP1.2 in cultures exposed 
to NGF for 2  wk or more was not enhanced further by 2  h 
of treatment  with any of these agents  (data  not shown). 
Discussion 
Recognition of  MAP1.2 on Low Percentage 
Polyacrylamide/Urea Gels 
We  have  identified  the  high  molecular  mass  protein, 
MAP1.2, in PC12 cells before and after NGF treatment and 
quantified both its levels and phosphorylation.  Our analysis 
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i has relied on the mobility of the protein in one-dimensional 
gels. The possibility that significant quantities of other pro- 
teins of equivalent electrophoretic mobility are present in the 
gels seems remote for several reasons. First, after immuno- 
precipitation with a specific antibody, only a small amount 
of protein of electrophoretic mobility similar to MAPI.2 re- 
mains in the lysates of both control and NGF-treated cells 
(see Results). In addition, in response to long-term exposure 
to NGF, there is a shift in the mobility of MAP1.2 (by all 
methods of detection) such that little protein remains at the 
location in the gel corresponding to the position of MAP1.2 
from untreated cells. This mobility shift can be reversed by 
phosphatase treatment. Finally, our immunoblotting results, 
with the exception of that in Fig.  1 D, corroborate our quan- 
titative data based on scanning densitometry (cf. Fig.  l). 
NGF-specific Phosphorylation of  MAP1.2 
Previous observations have revealed that NGF produces a 
striking long-term increase in the relative incorporation of 
phosphate into PCI2 cell MAP1.2 (3,  10,  15). We show here 
that this is in part due to a dual effect on phosphorylation. 
There is a rapid effect of NGF on phosphate incorporation 
into this protein followed by a slower increase in this parame- 
ter. We have estimated that by two wk or more of treatment, 
the average NGF-induced increase in phosphate groups is 
about  fourfold per  molecule.  Our  data  indicate  that  this 
reflects changes in steady-state levels rather than turnover. 
Our results indicate that the rapid enhancement of phos- 
phorylation is  NGF specific and cannot be reproduced by 
EGF or a variety of agents that lead to activation of several 
well-characterized protein kinases. EGF, insulin, and cAMP 
derivatives have also been shown to be unable to mimic the 
long-term effect of NGF on MAP1.2 (15). Each of the agents 
used,  in  contrast,  stimulates  phosphorylation changes  of 
other PC12 cell proteins (16, 20, 24). This suggests that the 
NGF-enhanced phosphorylation of MAPI.2 is mediated ei- 
ther via a novel protein kinase or via inactivation of a rather 
specific phosphoprotein phosphatase. 
The present findings may be compared with those con- 
cerning other microtubule elements.  With long-term NGF 
treatment of PC12 cells, beta-tubulin and chartin MAPs also 
undergo enhanced phosphorylation (1,  3,  7).  In  the  latter 
case,  this  is due to a  large increase  in  the  levels of more 
highly  phosphorylated  isoforms  (3).  Phosphorylation  of 
chartin MAPs is rapidly inhibited by application of Li  ÷ (7), 
activators of adenylate cyclase (14),  or agents that lead to 
microtubule disassembly (1). In contrast, the phosphoryla- 
tions  of  MAP1.2  and  beta-tubulin  are  not  significantly 
affected by such treatments. 
Multiple Forms  of  MAP1.2 in PC12 Cells 
The resolution of high molecular mass proteins provided by 
the low percentage acrylamide/4 M urea gels used here has 
revealed multiple forms of PC12 cell MAP1.2 with slight, but 
consistently detectable, differences in mobility. As indicated 
by our experiments with alkaline phosphatase, these differ- 
ences are due, at least in part, to phosphorylation, with the 
least phosphorylated forms having the greatest mobility. 
Our study also revealed that treatment with NGF brings 
about a shift in the proportion of MAP1.2 that migrates with 
slower electrophoretic mobility. This is consistent both with 
the influence of phosphorylation on the mobility of MAPI.2 
in gels and with the effect of NGF on MAP1.2 phosphoryla- 
tion. The observation that most of the MAP1.2 protein (as re- 
vealed by immunoblotting,  silver staining,  and by labeling 
with  [35S]methionine)  undergoes  this  shift  in  long-term, 
NGF-treated cultures is consistent with the finding that NGF 
increases the average number of phosphates per molecule, 
rather than merely increasing phosphate turnover. This also 
appears to be the case with short-term NGF exposure; the 
MAP1.2 detected by phosphate label in such cases showed 
a shift to lower mobility. 
Although we are presently unable to reliably estimate the 
proportions of the various forms of MAP1.2, it is clear that 
very little of the MAP1.2 in non-NGF-treated PC12 cultures 
is in the most slowly migrating, highly phosphorylated form 
and, as noted above, that in contrast, this form is the most 
prominent in long-term, NGF-treated cultures. Thus, while 
the tong-term effects of NGF on overall MAP1.2 levels and 
phosphorylation are each reasonably modest, it is important 
to note that the factor appears to bring about very substantial 
changes in the levels of individual forms of this protein. 
A presently unresolved issue is the effect of NGF treatment 
on the distribution of the multiple forms of MAP1.2 at early 
times.  That is,  by phosphate label, the short-term effect of 
NGF is to enhance phosphorylation of MAP1.2 and to retard 
its electrophoretic mobility, whereas, in contrast, by methio- 
nine label, little or no mobility shift is seen (cf. Fig. 4) under 
such conditions. One interpretation of these data is that at 
short times of treatment, NGF brings about a very large in- 
crease in phosphate incorporation into a relatively small pool 
of MAP1.  Thus, it may be that the early action of NGF is 
directed at a subfraction of MAP1.2 while the long-term ac- 
tions affect most of the cellular content of this protein. As 
noted below,  this  could be relevant to different functional 
roles of the highly phosphorylated forms. 
Regulation of  MAP1.2 Protein Levels by NGF 
In the initial description of NGF's long-term influence on 
MAP1.2  levels  in  PC12  cultures,  immunoprecipitation of 
[35S]methionine-labeled material  suggested  an  increase  in 
the  relative levels of MAP1.2  protein  (15). Subsequently, 
Drubin et al. (10) reported an NGF-promoted 20-fold relative 
increase in PC12  cell MAP1.2 levels based on quantitative 
immunoblotting using a MAP1 mAb. Lewis et al. (22) mea- 
sured MAP1  mRNA  in PC12  cells by means of a  specific 
• cDNA probe and found only a modest (<2-3-fold) increase 
in the relative amounts of this message. In the present work, 
we have used SDS-PAGE to directly compare the relative 
steady-state levels of MAP1.2 protein present in whole cell 
extracts  of nontreated  and  long-term,  NGF-treated  PCI2 
cells. This was achieved either by silver staining or by analy- 
sis of material  labeled with  [35S]methionine  for 3 d.  Both 
methods indicated a 3.0- to 3.5-fold increase in the relative 
levels of MAPI.2 protein. This, together with the '~fourfold 
NGF-promoted increase in phosphorylation per molecule, 
accounts for the overall 16-fold relative increase in incorpo- 
ration of phosphate into MAPI.2 in NGF-treated cultures. 
It is clear that there is a discrepancy between the present 
results and those of Drubin et al.  (10) regarding the extent 
to which NGF increases MAP1.2 protein levels. One possi- 
ble explanation is that the mAb used by Drubin et al. has a 
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This could lead to an underestimation of MAPI.2 protein lev- 
els in non-NGF-treated cells, since, as our study indicates, 
this species contains relatively little phosphate. This possi- 
bility is consistent with the results we obtained by immuno- 
blotting with the same mAb used by Drubin et al. (Fig. 1 D). 
That is, in contrast to several polyclonal antisera, this anti- 
body showed essentially no recognition of MAP1.2 in non- 
NGF-treated cells. It may be significant in this light that our 
estimation of the overall NGF-promoted relative increase of 
phosphate incorporation into MAP1.2 (16-fold) is similar to 
the 20-fold increase in MAP1.2 protein reported by Drubin 
et al.  Another potential source of the difference  in results 
could lie in the culture conditions. Compared with the pres- 
ent work, Drubin et al. (10) used PC12 cells propagated un- 
der different conditions and grown on a different substrate in 
a different medium. 
Possible Functional Roles for MAPI.2 Regulation 
by NGF 
There are several possible ways in which NGF-dependent en- 
hancement of MAP1.2 phosphorylation and steady-state pro- 
tein levels  may  be of functional significance.  One evident 
role is in neurite outgrowth.  The initiation of neurites re- 
quires the presence of microtubules. In parallel with its pro- 
motion  of  neurite  outgrowth  in  PC12  cultures,  NGF  in- 
creases the proportion of cellular tubulin that is assembled 
(3,  10) and promotes  the appearance of arrays  of bundled 
microtubules (13).  There is evidence that MAP1 may be in- 
volved  in  the  assembly  and  stabilization  of microtubules 
and/or in their cross-linking with one another or with other 
cellular elements  (28).  Thus,  by means  of its  interactions 
with microtubules, MAP1  may play a necessary role in the 
formation and growth of neurites. NGF's effects  on both the 
levels and phosphorylation state of MAP1.2 may be impor- 
tant in this regard.  In particular,  the enrichment of phos- 
phorylated  MAP1.2  in  PC12  cell  neurites  vs.  cell  bodies 
(Aletta, J. M., and L. A. Greene, unpublished observations) 
presents  some  interesting  possibilities.  For  instance,  the 
more  highly phosphorylated forms  of MAP1.2,  which are 
greatly enhanced in level by long-term NGF treatment, could 
be  more  functionally  active  in  their  interactions  with 
microtubules. Also supportive of a potential role for MAPI.2 
regulation in neurite outgrowth is the observation that fibro- 
blast growth factor, the only other agent known to induce the 
neuronal differentiation of PCI2 cells (33), promotes long- 
term  effects  similar  to  NGF  on  levels  of  highly  phos- 
phorylated MAPI.2  (30). 
In addition to such a possible structural  role for the long- 
term effects  of NGF on MAP1.2,  based on its rapidity and 
NGF selectivity, the early increase in MAP1.2 phosphoryla- 
tion could conceivably serve a signaling function. Interest- 
ingly, in this regard, a phosphorylated MAPl-like molecule 
has  been  localized  at  putative  sites  of mRNA  maturation 
within the nuclei of fibroblasts (31). In such cells, the phos- 
phoprotein appears  in  nuclei  after  growth  stimulation.  In 
PC12 cells, along with its promotion of neuronal differentia- 
tion, NGF regulates the expression of a variety of genes (21). 
Perhaps,  a  phosphorylated form  of MAP1.2  in  PC12  cell 
nuclei serves some function during the NGF-mediated regu- 
lation of gene expression.  In agreement with this proposi- 
tion, fibroblast growth factor,  the only other known agent to 
mimic NGF's pattern of gene regulation (21), also elicits the 
rapid phosphorylation of MAP1.2 (Rydel, R. E., and L. A. 
Greene, unpublished observations). It may also be relevant 
in this regard that some experimental evidence has been ob- 
tained that another cytoskeletal protein, actin, may function 
as an initiation factor within the nucleus (12). 
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